

Amendments to the Claims:

Please amend claims 18-20 as follows:

--18. (currently amended) A purified or recombinantly produced polypeptide comprising ~~an~~ a mutant cytokine amino acid sequence of human interleukin-2, which mutant cytokine amino acid sequence is encoded by a gene from a diseased cell, which amino acid sequence is a modification of an and differs by one to six amino acid residues compared to a normal cytokine amino acid sequence ~~amino acid sequence of a normal human interleukin-2, wherein the interleukin-2 gene encoding the mutant cytokine from the diseased cell hybridizes under stringent wash conditions of 6X SSC at 0° C to a gene encoding a normal cytokine human interleukin-2 gene.~~--

--19. (currently amended) The purified or recombinantly produced polypeptide of claim 18, wherein the diseased cell is ~~obtainable from~~ a leukemic leukocyte cell.--

--20. (currently amended) The purified or recombinantly produced polypeptide of claim 18, wherein the diseased cell is ~~obtainable from~~ a human malignancy cell.--

--37. (previously presented) The polypeptide of claim 18, which polypeptide exhibits either antiviral activity, growth inhibition activity or immunosuppressive activity.--

--38. (previously presented) The polypeptide of claim 18, which polypeptide is purified to homogeneity.--